

Date: 12.11.2024

To,

M/s. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400 001

Security Code: 524654

Dear Sir / Madam,

Sub: Outcome of Board Meeting held on November 12th, 2024

This is to inform that the Board of the Directors at their meeting held on Tuesday, November 12th, 2024, have:

1. Approved the unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024.
2. Approved for making application for listing of securities of the company on National stock exchange (NSE).
3. The Nomination Remuneration & Compensation Committee (NRC) of the company have approved the allotment of a total of 30,000 (Thirty Thousand) Equity shares of face value Rs.10/- each fully paid up against the exercise of vested Options of Employee stock option plan 2018. Pursuant to Regulation 30 read with Schedule III to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and Regulation 10(c) of Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, ("SEBI SBEB Regulations").

These shares shall rank Pari-passu, in all respects with the existing equity shares of the company.

Consequent to the above allotment, the paid-up share capital of the Company stands increased from **Rs. 103111540** to **Rs.103411540/-**. The detailed disclosure required under Regulation 30 of SEBI Listing Regulations and pursuant to Regulation 10(c) of SEBI SBEB Regulations are enclosed herewith as "**Annexure-I**" and "**Annexure-II**" respectively.

The Board Meeting commenced at 03.30 PM and concluded at 05:40 PM

Kindly take the aforesaid information on record in compliance of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.

Thanking you.

For Natural Capsules Limited

Shilpa Burman
Company Secretary & Compliance Officer



Annexure-I

Disclosures pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 in respect of allotment of 30,000 equity shares pursuant to exercise of options:

S.No	Particulars	Details
1	Brief details of options granted	30,000 options were granted under Employees Stock Option Plan, 2018, and each of the option upon its vesting, was exercisable into 1 (one) equity share of Rs. 10/-
2	Whether the scheme is in terms of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021	Yes
3	Total number of shares covered by these options	30,000 equity shares of face value of Rs.10/- each
4	Pricing formula / Exercise Price	The exercise price of the options was determined as Rs. 10/- per option in accordance with applicable Accounting Standards
5	Options vested	The options under the respective schemes vest over a period of 3 years from the date of grant. The present instance is allotment of shares upon exercise of 30000 vested options.
6	Time within which option may be exercised	The exercise period shall commence from the date of vesting and expire not later than 12 months from the vesting date.
7	Options exercised	30,000
8	Money realized by exercise of options	Rs.3,00,000/- (Rupees Three Lakhs rupees only)
9	The total number of shares arising as a result of exercise of option;	30,000
10	options lapsed;	Nil
11	variation of terms of options;	Not Applicable
12	brief details of significant terms;	<ul style="list-style-type: none"> The Shares allotted upon the Exercise of an Option will rank pari- passu in all respects with the then existing Shares of the Company. There shall be no lock in period of the Shares allotted pursuant to Exercise of Option under ESOP 2018. Until the allotment of the Shares (as evidenced by the appropriate entry in the books of the Company or of a duly authorized transfer agent of the Company) consequent to the exercise of the options, no right to vote or receive dividends or in any other manners enjoy the benefits / rights as a Shareholder shall exist with respect to the Options, notwithstanding the Exercise of the Option.



		<ul style="list-style-type: none"> Each Option once Vested, on Exercise shall entitle the Option Grantee to get one Share. The Option Grantee may, at any time during the Exercise Period, and subject to fulfillment of all applicable conditions in the Options Agreement and applicable laws, Exercise all or part of the Vested Options by submitting an Exercise Form, accompanied by payment of an amount equivalent to the Exercise Price and Taxes in respect of such Shares to the Nomination Remuneration and Compensation Committee.
	subsequent changes or cancellation or exercise of such options;	Exercise of options
	Diluted earnings per share pursuant to issue of equity shares on exercise of options	2.32 (in Rs.) The earnings as reported by the Company for Q2FY24 has been taken for the calculation of diluted earnings per share pursuant to issue of equity shares on exercise of options.



Annexure-II

Disclosure pursuant to Regulation 10(c) & Part E of Schedule I of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 in respect of allotment of 30,000 equity shares pursuant to exercise of options:

S.No	Particulars	Details
1	Company name and address of Registered Office	Natural Capsules Limited No.23,4 th Floor, Trident Towers, 100 Feet Road, Jayanagar 2 nd Block, Bangalore-560011
2	Name of the recognised Stock Exchanges on which the company's shares are listed	BSE Limited
3	Filing date of the statement referred in regulation 10(b) of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with the recognized Stock Exchange	17 th October 2018
4	Filing Number, if any	BSE In principle Approval No: DCS/IPO/JR/ESOP-IP/3283/2018-2019 dated:01/11/2018 for 300000 shares.
5	Title of scheme pursuant to which shares are issued, if any	Natural Capsules Limited -Employees Stock Option Plan 2018
6	Kind of security to be listed	Equity Shares
7	Par value of the shares	Rs.10/-
8	Date of issue of shares	12 th November 2024
9	Number of shares issued	30,000
10	Share Certificate No., if applicable	Not Applicable
11	Distinctive number of the share, if applicable	10324468 to 10354467
12	ISIN Number of the shares if issued in Demat	INE936B01015
13	Exercise price per share	10/-
14	Premium per share	
15	Total issued shares after this issue	10354467 equity shares of Face Value of Rs.10/- each
16	Total issued share capital after this issue	Rs.103544670/-
17	Details of any lock-in on the shares	Not Applicable
18	Date of expiry of lock-in	Not Applicable
19	Whether shares are identical in all respects to existing shares? If not, when will they become identical?	The equity shares allotted consequent to exercise of options shall rank pari-passu with the existing equity shares of the Company
20	Details of listing fees, if payable	Not Applicable



P. CHANDRASEKAR LLP

Chartered Accountants

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS.

TO

The Board of Directors,
Natural Capsules Limited,
Bangalore.

1. We have received the accompanying statement of unaudited financial results of **M/s. NATURAL CAPSULES LIMITED** ("the company") for quarter ended September 2024 and year to date from April 01, 2024 to 30th September 2024 ("the Statement"), which are included in the accompanying statement of unaudited Financial results. This statement has been prepared by the company pursuant to the requirement of Regulation 33 of the securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.
2. This statement is the responsibility of the company's Management and has been approved by the Board of Directors. This Statement has been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Bangalore / Chennai / Hyderabad

Head Office:
S-512-514, Manipal Centre, #47, Dikenson Road, Bangalore – 560042
☎ : 080-25585443 / 25597494

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard as specified under section 133 of the Companies Act 2013 read with relevant rules issued thereunder other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended including the manner in which it is to be disclosed , or that it contains any material misstatement.

For P. Chandrasekar LLP
Chartered Accountants
FRN No: 000580S/S20006



Arun R
Partner

Membership No: 208425

UDIN : 24208425BKAJTQ9959

Place - Bangalore

Date:12th November 2024



Bangalore / Chennai / Hyderabad

Head Office:

S-512-514, Manipal Centre, #47, Dikenson Road, Bangalore – 560042

☎ : 080-25585443 / 25597494

NATURAL CAPSULES LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23,100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLC014742

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER / SIX MONTHS ENDED SEP 30, 2024.

Rs. in Lakh

Sl. No.	PARTICULARS	Quarter Ended			Six Months Ended		Year Ended
		30th Sep 2024	30th June 2024	30th Sep 2023	30th Sep 2024	30th Sep 2023	31st Mar 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	4,102.98	3,913.59	3,751.66	8,016.56	7,522.02	15,380.63
2	Other Income	76.96	76.49	60.66	153.46	118.40	314.57
3	Total Income (1+2)	4,179.94	3,990.08	3,812.32	8,170.02	7,640.42	15,695.20
4	Expenses						
	a) Cost of Material consumed	2,110.83	2,041.72	2,040.18	4,152.54	4,020.33	8,331.61
	b) (Increase) / Decrease in stock in trade	-141.59	-46.47	-173.97	-188.05	-354.53	-613.40
	c) Purchase of stock-in-trade	-	-	-	-	-	-
	d) Employees benefits expense	320.55	323.09	288.88	643.64	575.32	1,231.79
	f) Finance cost	154.34	145.63	114.98	299.97	236.35	494.83
	g) Depreciation	215.54	209.28	215.98	424.82	426.63	856.85
	h) Other Expenses	1,318.78	1,123.18	1,072.28	2,441.96	2,150.13	4,354.06
	Total Expenses	3,978.45	3,796.43	3,558.33	7,774.88	7,054.24	14,655.73
5	Profit from ordinary activities after finance costs but before exceptional items	201.49	193.65	253.99	395.14	586.18	1,039.47
6	Exceptional Items Income / (Expenses)	-	-	-	-	-	-
7	Profit from ordinary activities before tax	201.49	193.65	253.99	395.14	586.18	1,039.47
8	Tax Expense	109.27	47.73	56.85	157.01	143.98	258.97
	- Current Tax	61.45	45.90	43.00	107.34	115.27	197.13
	-Income tax (Prior year)	-0.00	0.00	-	0.00	-	0.00
	- Deferred Tax	47.83	1.84	13.85	49.66	28.70	61.84
9	Net Profit (+) / Loss (-) from ordinary activities after tax	92.22	145.91	197.14	238.13	442.20	780.50
10	Other Comprehensive income (OCI)						
	a) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-	-	26.09
	b) Items that will be reclassified to profit or loss (net of tax)	-	-	-	-	-	-
11	Total Comprehensive Income (OCI) for the period	92.22	145.91	197.14	238.13	442.20	806.58
12	Paid-Up Equity Share Capital (face value per share Rs.10/-)	1,024.87	934.22	933.18	1,024.87	933.18	933.18
13	Earnings Per Share of (before & after extraordinary items) Rs. 10/-						
	(a) Basic	0.90	1.56	2.11	2.32	4.74	8.67
	(b) Diluted	0.90	1.56	2.11	2.32	4.74	8.67

Note:

- The unaudited standalone financial results of the Company for the quarter / six months ended 30th Sep, 2024 have been approved by the Board of Directors of the Company at its meeting held on 12th Nov, 2024. The results for the quarter / six months ended 30th Sep, 2024 presented have been reviewed by the Statutory Auditors of the Company. An unqualified opinion has been issued by them thereon.
- The unaudited standalone financial results for the quarter / six ended 30th Sep, 2024 have been prepared above in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules 2016. The above audited standalone Financial results are filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchange Website.
- Utilization of right issue funds by the Natural Capsules Ltd as on 30th Sep, 2024 is as follows: (Rs. In Lacs)
Particulars
Amount received (Excluding balance in Escrow A/c) 3,089.45
Amount Spent 3,089.45
Balance available as on 30.09.2024 -
- Utilization of preferential issue funds by the Natural Capsules Ltd as on 30th Sep, 2024 is as follows: (Rs. In Lacs)
Particulars
Amount received (Including balance in Escrow A/c) 2,921.33
Amount Spent 1,999.95
Balance available as on 30.09.2024 921.38
There is no deviation in the use of proceeds from the objects stated in the offer documents of the preferential issue.
- Previous years figures have been regrouped wherever necessary.
- Position of investor complaints for the quarter ended 30th Sep, 2024
Particulars
Pending as on 30.06.2024 Nil
Received during the quarter Nil
Resolved during the quarter Nil
Pending as on 30.09.2024 Nil

For and on behalf of the Board


Sunil L Mundra
Managing Director
DIN:00214304
Place : Bangalore
Date : 12-11-2024



NATURAL CAPSULES LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23,100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLCO14742

UNAUDITED STANDALONE STATEMENT OF ASSETS & LIABILITIES

Rs. In Lakh

S.No	Particulars	Note No.	As at Sep 30, 2024	As at Mar 31, 2024
A	ASSETS			
	Non-Current Assets			
	(a) Property, Plant and equipment	2	8,660.81	8,999.40
	(b) Capital Work in Progress		292.84	211.54
	(c) Right-of-use assets		145.17	4.49
	(d) Investment Property		0.00	0.00
	(e) Intangible Assets	3	17.52	47.53
	(f) Financial Assets		-	-
	(i) Investments	4	2,274.00	2,274.00
	(ii) Trade Receivables		-	-
	(iii) Loans	5	4,296.00	2,236.16
	iv Other financial assets	6	223.09	221.09
	(g) Deferred Tax Assets (Net)		-	-
	(h) Other Non-Current Assets	7	9.40	9.21
	Total non-Current Assets		15,918.83	14,003.42
	Current Assets			
	(a) Inventories	8	1,955.89	1,750.71
	(b) Financial Assets		-	-
	(i) Investments		-	-
	(ii) Trade Receivables	9	6,254.59	5,355.70
	(iii) Cash and Cash Equivalents	10	941.01	219.47
	(iv) Bank balances other than (iii) above	11	205.99	705.04
	(v) Loans	0	-	-
	(v) Other Financial assets		-	-
	(c) Current tax assets (Net)		-	-
	(d) Other current Assets	12	1,080.29	1,091.67
	Total Current Assets		10,437.78	9,122.59
	TOTAL ASSETS		26,356.60	23,126.00
B	EQUITY AND LIABILITIES			
	Equity			
	(a) Equity Share Capital	13	1,024.87	933.18
	(b) Other Equity	14	15,353.49	12,253.08
	(c) Money Received against Share warrants		-	-
	Total Equity		16,378.35	13,186.26
	Liabilities			
	Non-Current Liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	15	2,294.81	2,646.53
	(ia) Lease Liabilities		148.77	1.33
	(ii) Trade Payables		-	-
	(iii) Other Financial Liabilities	0	-	-
	(c) Provisions	17	-	-
	(b) Deferred Tax Liabilities		388.87	339.21
	(d) Other Non-Current liabilities		-	-
	Total Non-Current Liabilities		2,832.46	2,987.07
	Current Liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	19	2,982.71	3,548.80
	(ia) Lease Liabilities		-	-
	(ii) Trade Payables		-	-
	Dues of micro enterprises and small enterprises	20	-	-
	Dues of creditors other than micro enterprises and small enterprises		3,570.30	2,963.72
	(iii) Other Financial Liabilities	21	10.72	27.73
	(b) Other Current Liabilities	23	362.00	266.26
	(c) Provisions	22	14.93	18.39
	(d) Current tax liabilities (Net)		205.14	127.78
	Total Current Liabilities		7,145.80	6,952.68
	Total Liabilities		9,978.25	9,939.75
	TOTAL EQUITY AND LIABILITIES		26,356.60	23,126.00

For and on behalf of the Board


Sunil L. Mundra
Managing Director

DIN:00214304

Place : Bangalore

Date : 12-11-2024



NATURAL CAPSULES LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23,100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLCO14742

UNAUDITED STANDALONE CASH FLOW STATEMENT FOR SIX MONTHS ENDED 30TH SEP, 2024

Rs. In Lacs

Particulars	For six months ended 30th Sep, 2024		For six months ended 30th Sep, 2023	
A. Cash flow from operating activities				
Profit before tax		395.14		586.18
Adjustments for:				
Adjustments for depreciation and amortisation expense	424.82		426.63	
Adjustments for finance costs	299.97		236.35	
Profit on sale of Fixed Assets (net)	-		-0.00	
Interest Income	-136.67		-13.51	
Bad Debts & Provision for Doubtful Debts	20.48		0.43	
Profit on sale of investments	-		-	
ESOP	22.23		-	
Remeasurement (losses)/gains in Lease rent	-		-	
Re-measurement of the defined benefit plan	-		-	
Unrealised exchange (gain) / loss	-		-	
		630.83		649.90
Operating profit before working capital changes		1,025.97		1,236.08
Changes in working capital				
Adjustments for increase / (decrease) in				
Adjustments for decrease (increase) in trade receivables, current	-919.37		-204.68	
Adjustments for decrease (increase) in inventories	-205.18		-549.80	
Adjustments for other bank balances	499.05		2.55	
Adjustments for decrease (increase) in other current assets	11.38		-120.68	
Adjustments for decrease (increase) in other non-current assets	-0.19		-1.18	
Adjustments for other financial assets, non-current	-2.00		54.26	
Adjustments for increase (decrease) in trade payables, current	606.58		97.07	
Adjustments for increase (decrease) in other current liabilities	95.75		54.27	
Adjustments for increase (decrease) in other non-current liabilities	-		-	
Adjustments for provisions, current	73.89		-1.83	
Adjustments for provisions, non-current	-		-	
Adjustments for other financial liabilities, current	-17.01		252.72	
Adjustments for other financial liabilities, non-current	-		-	
		142.90		-417.32
Cash generated from operations		1,168.87		818.76
Income taxes paid (refund)		107.34		115.27
Net cash generated from operating activities		1,061.53		703.49
B. Cash flow from investing activities				
Purchase of property, plant and equipment	-123.90		-465.43	
Movements in Intangible Assets	-		-	
Movement in Right Use of Assets	-		-	
Proceeds from sales of property, plant and equipment	-		-	
Proceeds from sales of investment	-		-	
Changes in Financail assets- Advance paid	-2,059.84		-147.87	
Investment made	-		-0.00	
Interest received	136.67		13.51	
Dividends received	-		-	
		-2,047.08		-599.79
Net cash used in investing activities		-2,047.08		-599.79
C. Cash flow from Financing activities				
Proceeds from issue of Shares including premium	2,931.73		56.23	
Proceeds from borrowings	-917.81		203.75	
Repayments of borrowings	-		-	
Interest paid	-299.97		-236.35	
Dividends paid	-		-92.98	
Payments of finance lease liabilities	-6.86		-11.73	
		1,707.09		-81.08
Net cash used in financing activities		1,707.09		-81.08
Net (decrease) / increase in cash and cash equivalents (A+B+C)		721.55		22.62
Reconciliation				
Cash and cash equivalents as at beginning of the year		219.47		40.31
Cash and cash equivalents as at end of the year		941.01		62.93
Net increase / (decrease) in cash and cash equivalents		721.55		22.62

For and on behalf of the Board

Supil L Mundra
Managing Director
DIN:00214304
Place : Bangalore
Date : 12.11.2024



P. CHANDRASEKAR LLP

Chartered Accountants

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS.

TO

The Board of Directors,
Natural Capsules Limited
Bangalore

1. We have received the accompanying statement of Consolidated unaudited financial results of **M/s. NATURAL CAPSULES LIMITED** (the Parent) and its subsidiaries (the Parent and its subsidiaries together referred to as the Group), for the quarter ended September 2024 and year to date from April 01, 2024 to 30th September 2024 ("the Statement"), which are included in the accompanying statement of consolidated unaudited Financial results. This statement has been prepared by the company pursuant to the requirement of Regulation 33 of the securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.
2. This statement is the responsibility of the company's Management and has been approved by the Board of Directors. This Statement has been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Bangalore / Chennai / Hyderabad

Head Office:
S-512-514, Manipl Centre, #47, Dikenson Road, Bangalore – 560042
☎ : 080-25585443 / 25597494



4. The Statement includes the results of the following entities:

Name of the Entity	Relationship
Natural Phyto Pharma Private Limited	Subsidiary
Natural Biogenex Private Limited	Subsidiary

5. Based on our review conducted as above and based on the consideration of the review reports of the other auditors as given below in point no.6, nothing has come to our attention that causes us to believe that the Statement, prepared in accordance with applicable Indian accounting standards and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of one subsidiary included in the consolidated unaudited financial results, whose interim financial results reflect total assets of Rs.2.44 lacs ,total revenues of Rs. Nil for the Half year ended 30 September 2024, total net profit after tax of Rs. Nil for the Half Year ended 30 September 2024 as considered in the Statement. These interim financial results have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports furnished by the management. In our opinion and according to the Information and explanations given to us by management, these financial statements and other financial information are not material to the Group. Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the financial information certified by management.

For P. Chandrasekar LLP
Chartered Accountants
FRN No: 000580S/S20006

Arun R
Partner

Membership No: 208425
UDIN: 24208425BKAJTR2053
Place - Bangalore
Date: 12th November 2024



Bangalore / Chennai / Hyderabad

Head Office:
S-512-514, Manipal Centre, #47, Dikenson Road, Bangalore – 560042
☎ : 080-25585443 / 25597494

NATURAL CAPSULES LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23,100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560-011
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLCO14742

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER / SIX MONTHS ENDED SEP 30, 2024

Rs. In Lacs

Sl. No.	PARTICULARS	Quarter Ended			Six Months Ended		Year Ended
		30th Sep 2024	30th June 2024	30th Sep 2023	30th Sep 2024	30th Sep 2023	31st Mar 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	4,122.45	3,918.34	3,751.66	8,040.79	7,521.32	15,542.00
2	Other Income	10.59	18.35	34.59	28.95	51.96	193.62
3	Total Income (1+2)	4,133.04	3,936.70	3,786.25	8,069.74	7,573.27	15,735.62
4	Expenses						
	a) Cost of Material consumed	2,124.05	2,038.36	2,040.18	4,162.41	4,019.63	8,400.39
	b) (Increase) / Decrease in stock in trade	-141.19	-39.78	-173.97	-180.96	-354.53	-681.50
	c) Purchase of stock-in-trade	-	-	-	-	-	147.97
	d) Employees benefits expense	329.12	330.68	288.88	659.80	575.32	1,237.20
	f) Finance cost	164.61	148.76	116.17	313.37	248.92	512.94
	g) Depreciation	234.90	227.98	216.92	462.87	427.87	866.78
	h) Other Expenses	1,359.98	1,152.50	1,084.21	2,512.48	2,173.40	4,446.65
	Total Expenses	4,071.48	3,858.50	3,572.39	7,929.97	7,090.61	14,930.43
	Profit from ordinary activities after finance costs but before exceptional items	61.56	78.20	213.86	139.76	482.66	805.19
5	Exceptional Items Income / (Expenses)	-	-	-	-	-	-
6	Profit from ordinary activities before tax	61.56	78.20	213.86	139.76	482.66	805.19
7	Tax Expense	122.79	17.87	57.95	140.66	144.44	249.84
8	- Current Tax	74.54	33.39	44.09	107.94	115.74	197.13
	- Income tax (Prior year)	-	-	-	-	-	-
	- Deferred Tax	48.25	-15.52	13.85	32.73	28.70	52.71
9	Net Profit (+) / Loss (-) from ordinary activities after tax	-61.22	60.33	155.91	-0.90	338.22	555.35
10	Other Comprehensive income (OCI)						
	a) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-	-	26.09
	b) Items that will be reclassified to profit or loss (net of tax)	-	-	-	-	-	-
11	Total Comprehensive Income (OCI) for the period	-61.22	60.33	155.91	-0.90	338.22	581.43
12	Paid-Up Equity Share Capital (face value per share Rs.10/-)	1,024.87	934.22	933.18	1,024.87	933.18	933.18
13	Earnings Per Share of (before & after extraordinary items) Rs. 10/-						
	(a) Basic	-0.60	0.65	1.67	-0.01	3.62	6.25
	(b) Diluted	-0.60	0.65	1.67	-0.01	3.62	6.25

Note:

- The unaudited consolidated financial results of the Company for the quarter/six months ended 30th Sep, 2024 have been approved by the Board of Directors of the Company at its meeting held on 12th Nov 2024. The results for the quarter / six months ended 30th Sep, 2024 presented have been reviewed by the Statutory Auditors of the Company. An unqualified opinion has been issued by them thereon.
- The unaudited consolidated financial results for the quarter/six months ended 30th Sep, 2024 have been prepared above in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules 2016. The above unaudited consolidated Financial results are filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchange Website.
- Utilization of right issue funds by the Natural Capsules Ltd as on 30th Sep, 2024 is as follows:

Particulars	Rs. In Lakh
Amount received (Excluding balance in Escrow A/c)	3,089.45
Amount Spent	3,089.45
Balance available as on 30.09.2024	-

There is no deviation in the use of the proceeds from the objects stated in the offer documents for the rights issue.
- Utilization of preferential issue funds by the Natural Capsules Ltd as on 30th Sep, 2024 is as follows:

Particulars	Rs. In Lakh
Amount received (Including balance in Escrow A/c)	2,921.33
Amount Spent	1,999.95
Balance available as on 30.09.2024	921.38

There is no deviation in the use of the proceeds from the objects stated in the offer documents for the preferential issue.
- Previous years figures have been regrouped wherever necessary.
- Position of investor complaints for the quarter ended 30th Sep, 2024

Particulars	
Pending as on 30.06.2024	Nil
Received during the quarter	Nil
Resolved during the quarter	Nil
Pending as on 30-09-2024	Nil

For and on behalf of the Board

Sunil L Mudra
Managing Director
DIN: 00214304
Place: Bangalore
Date : 12-11-2024



NATURAL CAPSULES LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23,100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLCO14742

UNAUDITED CONSOLIDATED STATEMENTS OF ASSETS & LIABILITIES

Rs in Lakh

S.No	Particulars	Note No.	As at Sep 30, 2024	As at Mar 31, 2024
A	ASSETS			
	Non-Current Assets			
	(a) Property, Plant and equipment	2	9,856.77	10,224.46
	(b) Capital Work in Progress		16,353.23	14,380.99
	(c) Right-of-use assets		145.17	4.49
	(d) Investment Property	3	-	-
	(e) Intangible Assets	2	17.52	47.53
	(f) Financial Assets		-	-
	(i) Investments	5	273.00	273.00
	(ii) Trade Receivables		-	-
	(iii) Loans		-	-
	(iv) Other financial assets	6	316.61	336.02
	(g) Deferred Tax Assets (Net)		-	-
	(h) Other Non-Current Assets	7	9.40	9.21
	Total non-Current Assets		26,971.70	25,275.69
	Current Assets			
	(a) Inventories	8	2,209.11	1,903.56
	(b) Financial Assets		-	-
	(i) Investments		-	-
	(ii) Trade Receivables	9	6,309.92	5,446.95
	(iii) Cash and Cash Equivalents	10	944.87	225.48
	(iv) Bank balances other than (iii) above	11	461.11	1,108.51
	(v) Loans	12	-	-
	(v) Other Financial assets	13	-	-
	(c) Current tax assets (Net)	14	-	-
	(d) Other current Assets	15	3,568.87	3,692.32
	Total Current Assets		13,493.88	12,376.83
	TOTAL ASSETS		40,465.57	37,652.52
B	EQUITY AND LIABILITIES			
	Equity			
	(a) Equity Share Capital	16	1,024.87	933.18
	(b) Other Equity	17	22,323.21	19,446.83
	(c) Non Controlling Interest		2,485.41	2,500.41
	Total Equity		25,833.48	22,880.42
	Liabilities			
	Non-Current Liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	18	6,195.13	6,793.31
	(i) Lease Liabilities		148.77	1.33
	(ii) Trade Payables		-	-
	(iii) Other Financial Liabilities	19	-	-
	(c) Provisions	20	-	-
	(b) Deferred Tax Liabilities		362.80	330.07
	(d) Other Non-Current liabilities		-	-
	Total Non-Current Liabilities		6,706.70	7,124.72
	Current Liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	21	3,628.88	4,106.16
	(i) Lease Liabilities		-	-
	(ii) Trade Payables		-	-
	Dues of micro enterprises and small enterprises	22	-	-
	Dues of creditors other than micro enterprises and small enterprises	22	3,617.75	3,041.84
	(iii) Other Financial Liabilities	23	13.49	29.22
	(b) Other Current Liabilities	25	452.34	324.87
	(c) Provisions	24	14.93	18.39
	(d) Current tax liabilities (Net)		198.00	126.91
	Total Current Liabilities		7,925.39	7,647.38
	Total Liabilities		14,632.09	14,772.10
	TOTAL EQUITY AND LIABILITIES		40,465.57	37,652.52

For and on behalf of the Board


Sunil L Mundra
Managing Director
DIN: 00214304
Place: Bangalore
Date : 12-11-2024



NATURAL CAPSULES LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23,100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLCO14742

UNAUDITED CONSOLIDATED CASH FLOW STATEMENT FOR SIX MONTHS ENDED 30TH SEP, 2024

Rs. in Lakh

Particulars	For six months ended 30th Sep, 2024		For six months ended 30th Sep, 2023	
A. Cash flow from operating activities				
Profit before tax		139.76		482.66
Adjustments for:				
Adjustments for depreciation and amortisation expense	462.87		427.87	
Adjustments for finance costs	313.37		248.92	
Profit on sale of Fixed Assets (net)	-		-0.00	
Interest Income	-6.20		-86.55	
Bad Debts	20.48		0.43	
ESOP	22.23		-	
Re-measurement of the defined benefit plan	-		-	
Unrealised exchange (gain) / loss	-		-	
		812.76		590.67
Operating profit before working capital changes		952.52		1,073.33
Changes in working capital				
Adjustments for increase / (decrease) in				
Adjustments for decrease (increase) in trade receivables, current	-883.44		-204.68	
Adjustments for decrease (increase) in inventories	-305.55		-591.14	
Adjustments for other bank balances	647.40		-1,012.43	
Adjustments for decrease (increase) in other current assets	123.45		-476.53	
Adjustments for decrease (increase) in other non-current assets	-0.19		-1.18	
Adjustments for other financial assets, non-current	19.41		-19.95	
Adjustments for increase (decrease) in trade payables, current	575.91		113.57	
Adjustments for increase (decrease) in other current liabilities	127.47		112.72	
Adjustments for increase (decrease) in other non-current liabilities	-		-	
Adjustments for provisions, current	67.63		1.52	
Adjustments for provisions, non-current	-		-	
Adjustments for other financial liabilities, current	-15.73		-411.07	
Adjustments for other financial liabilities, non-current	-		-	
		356.37		-2,489.18
Cash generated from operations		1,308.89		-1,415.85
Income taxes paid (refund)		107.94		115.74
Net cash generated from operating activities		1,200.96		-1,531.59
B. Cash flow from investing activities				
Purchase of property, plant and equipment	-2,023.80		-3,532.66	
Movements in Intangible Assets	-		31.74	
Movement in Right Use of Assets	-		10.96	
Proceeds from sales of property, plant and equipment	-		-	
Proceeds from sales of investment	-		-	
Changes in Financial assets- Advance paid	-		-	
Investment made	-		-	
Interest received	6.20		86.55	
Dividends received	-		-	
		-2,017.60		-3,403.41
Net cash used in investing activities		-2,017.60		-3,403.41
C. Cash flow from Financing activities				
Proceeds from issue of Shares including premium	2,931.73		56.23	
Proceeds from borrowings	-1,075.46		202.90	
Repayments of borrowings	-		-	
Interest paid	-313.37		-248.92	
Proceeds from changes in ownership interests in subsidiaries	-		5,000.00	
Dividends paid	-		-92.98	
Payments of finance lease liabilities	-6.86		-11.73	
		1,536.03		4,905.50
Net cash used in financing activities		1,536.03		4,905.50
Net (decrease) / increase in cash and cash equivalents (A+B+C)		719.39		-29.50
Reconciliation				
Cash and cash equivalents as at beginning of the year		225.48		147.77
Cash and cash equivalents as at end of the year		944.87		118.27
Net Increase / (decrease) in cash and cash equivalents		719.39		-29.50

For and on behalf of the Board

Sunil L. Mundra
Managing Director
DIN: 00214304
Place: Bangalore
Date : 12-11-2024

